Enliven Therapeutics Inc.
Organization details
- Legal name
- Enliven Therapeutics Inc.
- Former names
- IMARA Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Burlingame
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ELVN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001672619
- EIN
- 81-1523849
Board of directors
-
Andrew J. Schwab · DirectorSince 2023
-
Andrew John Phillips · DirectorSince 2023
-
Helen Louise Collins · DirectorSince 2023
-
J. Scott Garland · DirectorSince 2026
-
Jake Bauer · DirectorSince 2023
-
Joseph P. Lyssikatos · Director · CHIEF SCIENTIFIC OFFICERSince 2023
-
Kristine M. Ball · DirectorSince 2026
-
Lori Anne Kunkel · DirectorSince 2024
-
Mika K. Derynck · DirectorSince 2023
-
Rahul D. Ballal · DirectorSince 2023
-
Richard A. Fair · Director · PRESIDENT AND CEOSince 2025
-
Richard A. Heyman · DirectorSince 2023
-
Rishi Gupta · DirectorSince 2023
-
Samuel Kintz · Director · PRESIDENT AND CEOSince 2023
Chief executives
Director election results
Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
64.7%
-
99.7%
Board connections
9 of this board's directors also sit on 15 other boards. 15 are in the same sector.
-
Oric Pharmaceuticals Inc. Same sectorvia Lori Anne Kunkel and Richard A. Heyman
-
ALX Oncology Holdings Inc. Same sectorvia J. Scott Garland
-
Agios Pharmaceuticals Inc. Same sectorvia Rahul D. Ballal
-
BridgeBio Oncology Therapeutics Inc. Same sectorvia Jake Bauer
-
CAMP4 Therapeutics Corporation Same sectorvia Andrew J. Schwab
-
Immunovant Inc. Same sectorvia Jake Bauer
-
Kura Oncology Inc. Same sectorvia Helen Louise Collins
-
LB Pharmaceuticals Inc Same sectorvia J. Scott Garland
-
MoonLake Immunotherapeutics Same sectorvia Andrew John Phillips
-
Nurix Therapeutics Inc. Same sectorvia Lori Anne Kunkel
-
Olema Pharmaceuticals Inc. Same sectorvia J. Scott Garland
-
OnKure Therapeutics Inc. Same sectorvia Andrew John Phillips
-
Oruka Therapeutics Inc. Same sectorvia Kristine M. Ball
-
PMV Pharmaceuticals Inc. Same sectorvia Richard A. Heyman
-
Skye Bioscience Inc. Same sectorvia Andrew J. Schwab
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $76,741,066
- 74 sales by 10 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 30, 2026 | Lori Anne Kunkel Director | Option exercise | +3,741 | $1.12 | $4,190 |
| Oct 30, 2026 | Lori Anne Kunkel Director | Option exercise | +7,300 | $18.30 | $133,590 |
| Oct 19, 2026 | Helen Louise Collins Officer (CHIEF MEDICAL OFFICER) | Option exercise | +5,000 | $2.48 | $12,400 |
| Oct 19, 2026 | Hohl Benjamin Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +6,018 | $14.85 | $89,367 |
| Oct 19, 2026 | Helen Louise Collins Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −5,000 | $38.47 | $192,342 |
| Oct 19, 2026 | Hohl Benjamin Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −6,018 | $38.48 | $231,546 |
| Oct 1, 2026 | J. Scott Garland Director | Option exercise | +13,000 | $15.47 | $201,110 |
| Oct 1, 2026 | J. Scott Garland Director | Open-market sale | −13,000 | $46.67 | $606,719 |
| Sep 17, 2026 | Helen Louise Collins Officer (CHIEF MEDICAL OFFICER) | Option exercise | +5,000 | $2.48 | $12,400 |
| Sep 17, 2026 | Hohl Benjamin Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +3,982 | $14.85 | $59,133 |
| Sep 17, 2026 | Helen Louise Collins Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −2,916 | $50.03 | $145,887 |
| Sep 17, 2026 | Hohl Benjamin Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −3,535 | $50.03 | $176,856 |
| Sep 17, 2026 | Helen Louise Collins Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −1,844 | $50.71 | $93,509 |
| Sep 17, 2026 | Hohl Benjamin Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −2,194 | $50.72 | $111,280 |
| Sep 17, 2026 | Helen Louise Collins Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −240 | $51.48 | $12,355 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Enliven Therapeutics Inc.
Who is the CEO of Enliven Therapeutics Inc.?
Richard A. Fair has been Enliven Therapeutics Inc.'s PRESIDENT AND CEO since December 2025.
How many directors are on Enliven Therapeutics Inc.'s board?
Enliven Therapeutics Inc.'s board has 14 directors: Andrew J. Schwab, Andrew John Phillips, Helen Louise Collins, J. Scott Garland, Jake Bauer, Joseph P. Lyssikatos, Kristine M. Ball, Lori Anne Kunkel, Mika K. Derynck, Rahul D. Ballal and 4 others.
Are Enliven Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Enliven Therapeutics Inc. insiders made no open-market purchases and sold $76.7 million of shares in 74 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="enliven-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.